US Patent
US7300935 — Thienopyrimidine compounds and use thereof
Composition of Matter · Assigned to Takeda Pharmaceutical Co Ltd · Expires 2029-01-28 · 3y remaining
Vulnerability score
0/100
Ironclad — strong claim type, well-established, deep family
What this patent protects
This patent protects a class of thienopyrimidine compounds, specifically those with a certain chemical structure, as represented by a given formula.
USPTO Abstract
The present invention provides a compound represented by the formula: wherein R<SUP>1 </SUP>is a C<SUB>1-4</SUB>alkyl; R<SUP>2 </SUP>is (1) a 5- to 7-membered nitrogen-containing heterocyclic group which may have a substituent selected from the group consisting of (1') a halogen, (2') a hydroxy group, (3') a C<SUB>1-4</SUB>alkyl and (4') a C<SUB>1-4</SUB>alkoxy, (2) a phenyl which may have a substituent selected from the group consisting of (1') a halogen, (2') a C<SUB>1-4</SUB>alkoxy-C<SUB>1-4</SUB>alkyl, (3') a mono-C<SUB>1-4</SUB>alkyl-carbamoyl-C<SUB>1-4</SUB>alkyl, (4') a C<SUB>1-4</SUB>alkoxy and (5') a mono-C<SUB>1-4</SUB>alkylcarbamoyl-C<SUB>1-4</SUB>alkoxy, or the like; R<SUP>3 </SUP>is a C<SUB>1-4</SUB>alkyl; R<SUP>4 </SUP>is a C<SUB>1-4</SUB>alkoxy, or the like; n is an integer of 1 to 4; or a salt thereof, as a thienopyrimidine compound having gonadotropin-releasing hormone antagonistic activity.
Drugs covered by this patent
- Estrace (ESTRADIOL) · Pfizer
- Orgovyx (relugolix) · MYOVANT SCIENCES
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.